Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia

被引:39
作者
Kinoshita, Y
Hashimoto, T
Kawamura, A
Yuki, M
Amano, K
Sato, H
Oshima, N
Takashima, T
Kitajima, N
Abe, K
Suetsugu, H
机构
[1] Shimane Univ, Sch Med, Dept Gastroenterol & Hepatol, Shimane 6938501, Japan
[2] Unnan Gen Hosp, Dept Med, Unnan, Japan
[3] Ono Municipal Hosp, Dept Med, Ono, Japan
[4] Hirata Municipal Hosp, Dept Med, Izumo, Shimane, Japan
[5] Masuda Redcross Hosp, Dept Med, Masuda, Japan
[6] Ohda Municipal Hosp, Dept Med, Ohda, Japan
[7] Kasai Municipal Hosp, Dept Med, Kasai, Japan
关键词
D O I
10.1111/j.1365-2036.2005.02472.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: An effective therapeutic strategy for functional dyspepsia (FD) has not been well-established. Aim: We investigated and compared the therapeutic effects of famotidine, mosapride and tandospirone for the control of dyspeptic symptoms. Methods: Fully examined FD patients of outpatient clinics at seven different medical centres were enrolled in the study. They were randomly assigned to three groups based on the type of drug administered: famotidine, mosapride and tandospirone. The effects of treatment over 4 weeks were assessed by visual analogue scales. Results: All of the drugs showed beneficial effects, although famotidine was the most effective for symptom relief, which was significantly greater than tandospirone, while the effect of mosapride was similar to that of famotidine. No subtype of FD showed a better response to a particular type of drug. Conclusions: For the treatment of FD, famotidine demonstrated the best therapeutic effect, followed by mosapride, while that of tandospirone was significantly lower.
引用
收藏
页码:37 / 41
页数:5
相关论文
共 13 条
[1]   A Community-Based, Controlled Study of the Epidemiology and Pathophysiology of Dyspepsia [J].
Castillo, Emma Janet ;
Camilleri, Michael ;
Locke, G. Richard, III ;
Burton, Duane D. ;
Stephens, Debra A. ;
Geno, Debra M. ;
Zinsmeister, Alan R. .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (11) :985-996
[2]  
Chen Shi-yao, 2004, Zhonghua Liu Xing Bing Xue Za Zhi, V25, P165
[3]   Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia [J].
Farup, PG ;
Wetterhus, S ;
Osnes, M ;
Ulshagen, K .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1997, 32 (08) :755-759
[4]   CISAPRIDE OR CIMETIDINE IN THE TREATMENT OF FUNCTIONAL DYSPEPSIA - RESULTS OF A DOUBLE-BLIND, RANDOMIZED, SWISS MULTICENTER STUDY [J].
HALTER, F ;
MIAZZA, B ;
BRIGNOLI, R .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1994, 29 (07) :618-623
[5]   Prevalence of non-ulcer dyspepsia in the Japanese population [J].
Hirakawa, K ;
Adachi, K ;
Amano, K ;
Katsube, T ;
Ishihara, S ;
Fukuda, R ;
Yamashita, Y ;
Shiozawa, S ;
Watanabe, M ;
Kinoshita, Y .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 1999, 14 (11) :1083-1087
[6]   A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia [J].
Holtmann, G ;
Gschossmann, J ;
Mayr, P ;
Talley, NJ .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (09) :1641-1648
[7]   Levosulpiride and Cisapride in the Treatment of Dysmotility-Like Functional Dyspepsia: A Randomized, Double-Masked Trial [J].
Mearin, Fermin ;
Rodrigo, Luis ;
Perez-Mota, Arturo ;
Balboa, Agustin ;
Jimenez, Isabel ;
Jose Sebastian, Juan ;
Paton, Caro .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2004, 2 (04) :301-308
[8]   H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia:: a meta-analysis of randomized controlled clinical trials [J].
Redstone, HA ;
Barrowman, N ;
van Zanten, SJO .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (09) :1291-1299
[9]   Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans [J].
Tack, J ;
Broekaert, D ;
Coulie, B ;
Fischler, B ;
Janssens, J .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (04) :603-608
[10]   Pathophysiology and treatment of functional dyspepsia [J].
Tack, J ;
Bisschops, R ;
Sarnelli, G .
GASTROENTEROLOGY, 2004, 127 (04) :1239-1255